Home > Boards > US OTC > Biotechs > Cytodyn Inc. (CYDY)

Black-Ops, your posts have been very spot on

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Chuckles759 Member Profile
 
Followed By 20
Posts 612
Boards Moderated 0
Alias Born 05/09/20
160x600 placeholder
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 7/8/2020 5:07:43 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/8/2020 4:31:38 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/19/2020 5:19:36 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/8/2020 7:24:49 PM
Proxy Soliciting Materials (revised) (prer14a) Edgar (US Regulatory) - 6/8/2020 5:28:53 PM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 6/8/2020 6:02:50 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/2/2020 5:01:56 PM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 6/2/2020 8:01:17 AM
Amended Statement of Changes in Beneficial Ownership (4/a) Edgar (US Regulatory) - 5/15/2020 8:47:08 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 5/12/2020 6:00:59 AM
Securities Registration Statement (simplified Form) (s-3/a) Edgar (US Regulatory) - 4/30/2020 5:28:39 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/28/2020 5:29:47 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/27/2020 5:03:47 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/23/2020 5:08:55 PM
Amended Statement of Beneficial Ownership (3/a) Edgar (US Regulatory) - 4/22/2020 7:35:43 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/22/2020 5:38:33 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 4/22/2020 5:16:18 PM
The Next Hot Sector is Upon us and You Will Never Guess What It is InvestorsHub NewsWire - 4/16/2020 8:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 4/9/2020 4:45:19 PM
Other Filing Edgar (US Regulatory) - 4/9/2020 10:24:51 AM
Other Filing Edgar (US Regulatory) - 4/9/2020 10:24:21 AM
Amended Small Company Offering and Sale of Securities Without Registration (d/a) Edgar (US Regulatory) - 4/7/2020 10:48:57 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/6/2020 5:06:53 PM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 3/30/2020 5:25:25 PM
Small Company Offering and Sale of Securities Without Registration (d) Edgar (US Regulatory) - 3/30/2020 4:08:15 PM
Chuckles759   Sunday, 05/10/20 02:03:27 AM
Re: Black-Ops post# 76824
Post # of 93396 
Black-Ops, your posts have been very spot on and obviously tempered with wisdom and experience.

Just focusing on the HIV treatment here. COVID is a completely different topic and would be awesome if that gets released for treatment ASAP.

Since current HIV patients (health care covered) need maintenance drugs to the tune of $15-25K/year, wouldn't a good price point be in the range of $300-$500/dose (one dose per week per year = $15,600 - $26,000) to make it comparable in price but vastly superior in benefit? Not sure of production and delivery costs, but amortizing the costs over a few years to near term debt service and incrementally reward shareholders make sense, IMHO.

Do you now if the FDA application for HIV included exclusivity? I know CytoDyn has requested 7-year exclusivity in GvHD in March 2020, but not aware of a request for HIV treatment.

These price points are somewhat in alignment with CytoDyn's PRO 140 brief from March 2018 page 3 and 15 (http://content.stockpr.com/cytodyn/media/a142a8575db88331c0585a336ca2ebfd.pdf).

I'm trying to pin market share/revenue for each indication....then try to fathom them all added up.


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist